FibroGen’s pamrevlumab failed to prove its efficacy in two Phase III trials prom...
In the intent-to-treat cohort, IMNN-001 plus chemotherapy offered a median 11.1-...
The FDA has set a PDUFA target action date of 30 January 2025 for Vertex’s acute...
The biopharmaceutical industry experienced varied revenue shifts in 2023, with s...
The European agency said that Leqembi’s efficacy was “not large enough” to outwe...
EMA’s COMP has adopted positive opinions for two orphan medicinal product design...
The European Commission (EC) has granted approval to a €2bn Dutch measure to pro...
The US FDA has granted approval for Luye Pharma’s ERZOFRI extended-release injec...
Bristol Myers Squibb (BMS) has posted net income attributable to the company of ...
The EMA CHMP has recommended approving MSD’s KEYTRUDA regimen as a first-line tr...
Osteoporosis is the most common metabolic bone disorder worldwide and is the lea...
SecureCHEK AI is a Category Award Winner in four areas in the 2024 Pharmaceutica...
Clinical trial trends point to studying combination therapies and lifestyle chan...
The CHMP recommendation is based on positive results from the Phase IIb EFFISAYI...
Several patients are navigating ways to access innovative gene therapies with th...
The company has fired 25% of its staff and plans to look for partnerships to fur...
